Rhabdomyolysis in a patient with advanced lung cancer treated with osimertinib: a case report

BACKGROUND: As a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), osimertinib is the standard treatment for patients with EGFR mutations. Diarrhea and rash are the most common side effects, and some rare adverse reactions have started appearing owing to their i...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, You, Liu, Yu, Zhao, Zichen, Zhang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087996/
https://www.ncbi.nlm.nih.gov/pubmed/37057122
http://dx.doi.org/10.21037/tlcr-22-916

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10087996/
https://www.ncbi.nlm.nih.gov/pubmed/37057122
http://dx.doi.org/10.21037/tlcr-22-916

Ejemplares similares